title: HPV vaccine recommendations.
abstract: On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck & Co, Inc, Whitehouse Station, NJ) be used routinely in males. The American Academy of Pediatrics has reviewed updated data provided by the Advisory Committee on Immunization Practices on vaccine efficacy, safety, and cost-effectiveness as well as programmatic considerations and supports this recommendation. This revised statement updates recommendations for human papillomavirus immunization of both males and females.
mesh_terms: D000293:Adolescent; D026683:Advisory Committees; D000367:Age Factors; D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D005544:Forecasting; D006291:Health Policy; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D017589:Immunization Programs / Q000592:standards* / Q000639:trends; D007115:Immunization Schedule; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D010349:Patient Compliance / Q000706:statistics & numerical data; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012737:Sex Factors; D014481:United States
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines